To further validate the effect of JAK2 inhibition on tumor growth in vivo, we performed xenograft assays with HCC-827 lung adenocarcinoma cells, which are driven by an activating mutation (E746-A750 deletion) in EGFR [31]. Here, JAK2 is linked to hepatocellular carcinoma.